A new study suggests that a simple blood test in midlife may one day help identify who is at higher risk of developing Alzheimer’s disease long before symptoms appear.
The discovery comes from researchers at UT Health San Antonio’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases and the New York University Grossman School of Medicine.
Their findings show that the activity of platelets—tiny blood cells involved in clotting—may be closely linked to early brain changes seen in Alzheimer’s disease.
Alzheimer’s is a slow-moving brain disease that usually begins many years before memory loss or confusion is noticeable. Because of this, scientists have been trying to find early warning signs that can be detected long before symptoms begin. One major clue lies in the health of blood vessels.
When blood vessels do not work properly—a condition called vascular dysfunction—many problems can follow, including blood clots, inflammation, high blood pressure, diabetes, atherosclerosis, and stroke. All of these conditions are known to increase the risk of Alzheimer’s, but until now, the exact biological connection has been unclear.
This study helps fill that gap. The researchers discovered that platelet aggregation, which means platelets clumping together to form clots, may play a key role in the early stages of Alzheimer’s disease.
The team’s work shows that stronger platelet clumping in the blood is linked to higher levels of amyloid and tau proteins in the brain. These two proteins are the main hallmarks of Alzheimer’s disease. Amyloid forms sticky plaques between brain cells, while tau forms tangles inside them, leading to cell damage and memory loss over time.
The study looked at 382 healthy adults with an average age of 56. All were part of the long-running Framingham Heart Study, a famous research project that has been tracking the health of thousands of people since 1948.
None of the participants had dementia, and none were taking medications that affect platelet activity. Researchers used a test called light transmission aggregometry, a common method for measuring platelet clumping.
The participants also underwent detailed brain scans using PET imaging—with tracers to detect amyloid and tau—and MRI scans to look for structural brain changes. The results showed a clear pattern: people whose platelets clumped together more strongly tended to have more amyloid and tau in their brains, even though they had no symptoms of Alzheimer’s yet.
However, this relationship was strongest among people with lower overall platelet activity. For those with higher platelet activity, the connection was weaker or less consistent. This suggests that the link between platelet behavior and Alzheimer’s risk may vary depending on individual biological differences.
These findings offer an important new understanding of how vascular problems might contribute to brain diseases. Since up to 75% of people diagnosed with Alzheimer’s also show signs of vascular damage, this new link with platelet activity strengthens the idea that blood vessel health plays a major role in brain aging.
Platelets may act as a bridge between vascular dysfunction and inflammation inside the brain, helping explain why the two often appear together.
What makes this discovery especially promising is that platelets are very easy to test. A simple blood sample from a person in their 40s or 50s could one day provide clues about whether their brain is undergoing early changes tied to Alzheimer’s disease.
If researchers can develop a reliable screening test, doctors might be able to identify high-risk individuals decades before symptoms start. This would open the door to early lifestyle changes, medical treatments, and preventive therapies targeted at inflammation and vascular health.
In analyzing the study’s findings, the research presents strong early evidence that platelet activity may predict early Alzheimer’s-related brain changes. The use of a well-established population like the Framingham Heart Study strengthens the credibility of the results, and the combination of PET and MRI scans provides clear biological markers.
However, the study also has limitations. It shows association, not causation, meaning scientists still need to understand how platelet changes directly influence amyloid and tau buildup.
The differing results across platelet activity levels show that more research is needed to figure out why the connection is stronger in some people than others. Still, these results suggest that blood-based clues in midlife could help identify at-risk individuals much earlier than existing methods.
Overall, this study highlights an exciting new direction for Alzheimer’s research. If future studies confirm these findings, platelet activity may become an important tool in early detection, prevention, and treatment approaches for Alzheimer’s disease.
If you care about Alzheimer’s, please read studies about Vitamin D deficiency linked to Alzheimer’s, vascular dementia, and Oral cannabis extract may help reduce Alzheimer’s symptoms.
For more information about brain health, please see recent studies about Vitamin B9 deficiency linked to higher dementia risk, and results showing flavonoid-rich foods could improve survival in Parkinson’s disease.
The study is published in Neurology.
Copyright © 2025 Knowridge Science Report. All rights reserved.
